Arun Agrawal In the US, the National Institute of Health's attempt to patent partial cDNA sequences corresponding to gene fragments in human brain tissue has sparked off a controversy which impinges on ethical issues and is critical to the evolution of the patent law on human interventions in naturally occurring substances.
To read the full text Login
New 3 Month Subscription
to Digital Archives at
₹826for India
$50for overseas users
Comments
EPW looks forward to your comments. Please note that comments are moderated as per our comments policy. They may take some time to appear. A comment, if suitable, may be selected for publication in the Letters pages of EPW.